Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic, and fatal interstitial lung disease characterized by progressive scarring of the lung parenchyma, leading to a relentless decline in lung function and respiratory failure. The prognosis for patients with IPF is poor, with a median survival of only three to five years following diagnosis if left untreated. For more than a decade, the pharmacological management of IPF was restricted to just two oral antifibrotic medications. These therapies slowed the rate of lung-function decline but did not halt or reverse disease progression, establishing a clinical baseline that left a significant need for therapeutic innovation.
Recently, the regulatory and commercial landscapes for IPF have experienced unprecedented change. The approval of a novel preferential phosphodiesterase 4B (PDE4B) inhibitor has introduced the first new mechanism of action for IPF in eleven years, while the primary patent expiry of the leading branded antifibrotic has opened the door to generic competition.
This pulmonology access landscape reviews the clinical, legal, and operational realities of managing IPF therapies in 2026. We examine the two-drug clinical backbone, the clinical evidence supporting the approval of nerandomilast (Jascayd), the patent litigation and skinny-label mechanics of the nintedanib (Ofev) generic cliff, the commercial distribution realities of specialty and orphan orals, and the clinical prior authorization (PA) and utilization management (UM) frameworks used by payers to regulate access to this evolving therapeutic class.
Executive Summary & Scenario Analysis
To align on the pricing and access dynamics for idiopathic pulmonary fibrosis (IPF) therapies, we must address the primary questions facing clinical pharmacy directors and benefit designers.
Scenario Question
Which IPF drugs are accessible in 2026, how does Jascayd fit, and what does the Ofev generic change?
Direct Answer
The IPF clinical backbone is built on two oral antifibrotics: nintedanib (Ofev, NDA 205832, approved October 15, 2014) and pirfenidone (Esbriet capsule approved 2014; tablet NDA 208780 approved January 11, 2017), with pirfenidone available as a cheap generic in the CMS NADAC registry (ranging from $1.25 per tablet for 267 mg to $4.12 per tablet for 801 mg). The first new therapeutic class in over a decade, nerandomilast (Jascayd, NDA 218764), was FDA-approved on October 7, 2025 as an oral preferential PDE4B inhibitor dosed at 18 mg twice daily (reducible to 9 mg twice daily for intolerance, except in patients also taking pirfenidone), based on FIBRONEER-IPF trial data demonstrating a significant reduction in the decline of forced vital capacity (FVC). The Ofev generic cliff occurred when the primary composition-of-matter patent (US Patent No. 6,762,180) expired on April 1, 2026, leading to FDA approvals for five generic nintedanib esylate applications (Cipla, Apotex, Dr. Reddy's, Sandoz, and Dexcel) on April 2, 2026. However, method-of-use patents for systemic sclerosis-associated interstitial lung disease (SSc-ILD; US Patent No. 10,154,990, expiring July 2029) and progressive fibrosing interstitial lung disease (PF-ILD) remain, meaning generics must carve out these indications ("skinny-labeling") while brand Ofev retains exclusivity. Brand Ofev is a specialty/orphan oral that returns 0 rows in the CMS NADAC registry, reflecting its exclusive specialty pharmacy distribution channel.
The Oral Antifibrotic Clinical Backbone: Nintedanib vs. Pirfenidone
Prior to the recent generic entries, the treatment of IPF was defined by two primary clinical trials and their subsequent FDA approvals, both occurring in October 2014. These two agents—nintedanib and pirfenidone—act through distinct antifibrotic pathways and have become the established clinical backbone for pulmonary fibrosis management.
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| THE TWO-AGENT IPF ANTIFIBROTIC STACK |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Active Ingredient (Brand) | Mechanism of Action | Key Registrational Trial | Clinical Efficacy & Primary Endpoint |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Nintedanib (Ofev) | Multikinase Inhibitor | INPULSIS-1 and INPULSIS-2 | Reduces the annual rate of FVC decline by approximately 50% compared to placebo (~115 mL/year slowed decline). |
| | (VEGFR, PDGFR, FGFR) | | |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Pirfenidone (Esbriet) | TGF-beta inhibitor | ASCEND | Reduces the proportion of patients with a >= 10% absolute decline in FVC or death by 48% at week 52. |
| | (Downregulates collagen)| | |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
Nintedanib (Ofev) and the INPULSIS Trials
Nintedanib (Ofev, NDA 205832) is a small-molecule tyrosine kinase inhibitor. It targets multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR alpha and beta), and fibroblast growth factor receptors (FGFR 1-3). By blocking these pathways, nintedanib inhibits the proliferation, migration, and differentiation of lung fibroblasts, which are the primary drivers of fibrotic remodeling.
The landmark Phase III INPULSIS-1 and INPULSIS-2 trials evaluated nintedanib (150 mg twice daily) compared to placebo in a total of 1,061 patients with IPF over 52 weeks.
- INPULSIS-1 Endpoint: The annual rate of FVC decline was -114.7 mL with nintedanib compared to -239.9 mL with placebo ($p < 0.001$).
- INPULSIS-2 Endpoint: The annual rate of FVC decline was -113.6 mL with nintedanib compared to -207.3 mL with placebo ($p < 0.001$).
- Safety and Tolerability: The primary adverse event was diarrhea, reported in 62% of patients receiving nintedanib compared to 18% in the placebo group, leading to dose reductions or discontinuations in a subset of patients.
Pirfenidone (Esbriet) and the CAPACITY/ASCEND Trials
Pirfenidone (Esbriet, NDA 208780 for the tablet formulation) is an oral synthetic small molecule with anti-inflammatory, antioxidant, and antifibrotic properties. Its precise molecular target remains partially uncharacterized, but it is known to inhibit the synthesis of transforming growth factor-beta (TGF-beta), a key pro-fibrotic cytokine that regulates collagen synthesis and fibrotic tissue deposition.
The clinical program for pirfenidone included the Phase III CAPACITY-004 and CAPACITY-006 trials, followed by the confirmatory Phase III ASCEND trial which evaluated pirfenidone (2403 mg daily, dosed as 801 mg three times daily) in 555 patients with IPF.
- ASCEND Outcome: At week 52, pirfenidone demonstrated a 48% reduction in the proportion of patients who experienced a decline of 10% or more in FVC or death compared to placebo.
- 6-Minute Walk Distance: Pirfenidone significantly reduced the decline in 6-minute walk distance ($p = 0.04$) and improved progression-free survival.
- Tolerability: The most common adverse events were nausea (36%), photosensitivity rash (30%), and dyspepsia.
In the CMS NADAC registry, pirfenidone is available as an inexpensive generic:
- 267 MG Tablet: Generic pirfenidone is priced at $1.24964 per tablet (Classification for Rate Setting = G).
- 801 MG Tablet: Generic pirfenidone is $4.11794 per tablet (Classification = G).
- 267 MG Capsule: Generic pirfenidone is $1.65150 per unit (Classification = G).
Payers leverage this generic availability by positioning generic pirfenidone as the preferred first-line antifibrotic option on Tier 1 formularies, requiring patients to try and fail generic pirfenidone or exhibit clinical intolerance before authorizing brand-name or specialty-only alternatives.
Jascayd: The First New IPF Mechanism in Eleven Years
On October 7, 2025, the FDA approved nerandomilast (Jascayd, NDA 218764) for the treatment of idiopathic pulmonary fibrosis (IPF). Nerandomilast represents the first new class of medication approved for IPF since nintedanib and pirfenidone entered the market in 2014.
Mechanism of Action: Preferential PDE4B Inhibition
Phosphodiesterase 4 (PDE4) is an intracellular enzyme that degrades cyclic adenosine monophosphate (cAMP), a key second messenger that regulates inflammatory and fibrotic signaling. Standard, non-selective PDE4 inhibitors (such as roflumilast or apremilast) are associated with severe gastrointestinal toxicity (diarrhea, nausea, weight loss) and psychiatric side effects, which limit their clinical utility in frail populations.
Nerandomilast is a novel oral small molecule designed to preferentially inhibit the PDE4B isoform over other PDE4 sub-families (A, C, and D). PDE4B is highly expressed in inflammatory cells and lung fibroblasts, where it drives cytokine release and fibrotic remodeling. Conversely, PDE4D is the primary isoform in the central nervous system and gastrointestinal tract, responsible for emesis and diarrhea. By preferentially targeting the B isoform, nerandomilast achieves robust anti-inflammatory and antifibrotic activity in the lung while minimizing systemic gastrointestinal toxicity.
Clinical Trial Evidence: FIBRONEER-IPF
The approval of nerandomilast was supported by the Phase III FIBRONEER-IPF trial (NCT05321069), a randomized, double-blind, placebo-controlled study that evaluated 1,177 patients with IPF over 52 weeks. Patients were randomized to receive nerandomilast (18 mg twice daily) or placebo. Crucially, the trial allowed patients to continue stable background therapy with either nintedanib or pirfenidone (representing about 70% of the cohort).
- Primary Endpoint (FVC Decline): At week 52, nerandomilast 18 mg twice daily significantly slowed the decline in FVC compared to placebo. The adjusted mean change in FVC was −114.7 mL in the nerandomilast 18 mg arm compared with −183.5 mL in the placebo group, an adjusted treatment difference of 68.8 mL (95% CI 30.3–107.4, p < 0.001).
- Tolerability and Side Effects: The most common adverse event was diarrhea, reported in 41% of patients in the 18 mg arm compared to 16% of those in the placebo arm. Nausea occurred in 18% vs. 7%. While elevated, these gastrointestinal events rarely led to treatment discontinuation due to the preferential PDE4B design.
- Co-Administration Dosing Caveat: The standard dose of Jascayd is 18 mg twice daily. However, for patients experiencing gastrointestinal intolerance, the label permits a dose reduction to 9 mg twice daily—with one critical caveat: dose reduction is not recommended in patients who are also taking pirfenidone due to a drug-drug interaction that increases pirfenidone exposure.
Indication Expansion: Progressive Pulmonary Fibrosis (FIBRONEER-ILD)
To expand nerandomilast's clinical footprint, Boehringer Ingelheim conducted the Phase III FIBRONEER-ILD trial (NCT05321082) in patients with progressive fibrosing interstitial lung diseases other than IPF — a condition now termed progressive pulmonary fibrosis (PPF) under the post-2022 international consensus nomenclature.
On December 19, 2025, the FDA approved a distinct application (NDA 220449) for Jascayd as a treatment for progressive pulmonary fibrosis in adults, making PPF the second approved indication alongside IPF. Clinical pharmacy directors should therefore recognize that both IPF and PPF are now on-label uses of nerandomilast; utilization management criteria that previously gated authorization to an IPF diagnosis alone should be updated to include PPF. For broader 2026 approval and generic-entry timelines, see the Q1-Q2 2026 FDA approvals and generic-entry review.
The Ofev Generic Cliff and Skinny-Label Patent Dynamics
Prior to 2026, Boehringer Ingelheim's Ofev (nintedanib) enjoyed a commercial monopoly in the multi-kinase antifibrotic space, generating approximately $3.76 billion in U.S. sales (IQVIA moving-annual-total January 2026). However, the primary composition-of-matter patent (US Patent No. 6,762,180) expired on April 1, 2026.
The April 2, 2026 Generic Approvals
On April 2, 2026, the FDA approved Abbreviated New Drug Applications (ANDAs) from five generic manufacturers to market nintedanib esylate capsules (equivalent to the 100 mg and 150 mg strengths of Ofev):
- Cipla Limited (ANDA 212609)
- Apotex Inc. (ANDA 219227)
- Dr. Reddy's Laboratories (ANDA 219283)
- Sandoz Inc. (ANDA 216915)
- Dexcel Pharma (ANDA 219819)
Multiple other developers hold tentative approvals (such as Glenmark ANDA 212555 and Accord ANDA 212732) that will convert to full approvals as secondary patent blockades resolve.
Skinny-Labeling and Remaining Method Patents
Although the core composition patent has expired, Boehringer Ingelheim retains secondary method-of-use patents listed in the FDA Orange Book. These method patents cover specific, non-IPF indications:
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Covered by US Patent No. 10,154,990, which does not expire until July 2029.
- Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Covered by additional formulation and method patents extending into the 2030s.
OFEV PATENT EXCLUSIVITIES & GENERIC MAPPING
[IPF Indication] [SSc-ILD / PF-ILD Indications]
- Composition Patent (US 6,762,180) - Method Patents (e.g. US 10,154,990)
- Expiration Date: April 1, 2026 - Expiration Date: July 2029 +
- Status: EXPIRED - Status: PATENT-PROTECTED
- Generic Availability: A-Rated Generics - Generic Availability: Brand Ofev Only
(Cipla, Apotex, Dr Reddy's, Dexcel) (Generics "Skinny-Labeled" out)
To enter the market, generic manufacturers utilized the Hatch-Waxman "skinny-label" pathway. They submitted section viii statements to carve out the patent-protected SSc-ILD and PF-ILD indications from their generic prescribing information. Consequently:
- Generic Nintedanib Esylate is approved and labeled only for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Brand Ofev remains the only formulation approved and labeled for SSc-ILD and PF-ILD.
Payer utilization management teams must implement strict diagnostic audits. If a pharmacy submits a claim for generic nintedanib with a diagnosis code for systemic sclerosis-associated ILD, the claim must be rejected, and the pharmacy must be routed to brand-name Ofev. Conversely, for an IPF diagnosis, generic nintedanib must be mandated as the preferred A-rated equivalent. For a comparable case study on generic transition and price erosion, see the Entresto generic-launch and price-erosion analysis.
Specialty/Orphan Distribution Realities and Access Tensions
Despite the entry of generic nintedanib, the drug's distribution differs from standard retail generics. Both Ofev and its generic equivalents are classified as specialty and orphan medications.
In the CMS NADAC snapshot, brand Ofev and generic nintedanib return 0 rows, indicating their complete exclusion from the retail-pharmacy acquisition-cost dataset. This is because Boehringer Ingelheim and the generic manufacturers utilize a closed, limited-distribution network composed of select specialty pharmacies (such as CVS Specialty, Accredo, AllianceRx Walgreens Prime, and CarelonRx).
Operational Access Barriers for Patients
- Prior Authorization Intensity: Payers enforce strict diagnostic validation, requiring spirometry reports documenting forced vital capacity (FVC) between 50% and 80% of predicted values, high-resolution computed tomography (HRCT) confirming a pattern of usual interstitial pneumonia (UIP), and documentation that the patient is a non-smoker.
- Specialty Pharmacy Coordination: Claim processing, clinical intake, and shipping coordination are managed by a single specialty hub. Delays in hub handoff or prior authorization review can lead to treatment interruptions, which are critical in a disease with progressive, irreversible lung function loss.
- Affordability & Copay Assistance: Because these medications are specialty orals, patient cost-sharing can exceed $1,000 per month under standard commercial co-insurance or Medicare Part D specialty tiers. Generic nintedanib developers do not offer copay cards of the same scale as branded hubs, forcing Medicare patients to rely on independent charitable foundations for co-pay assistance.
Pulmonology Pipeline: Beyond the Antifibrotic Base
As Jascayd establishes itself and nintedanib undergoes generic transition, the pulmonology pipeline contains next-generation mechanisms targeting distinct pathways in fibrotic lung disease.
Bexotegrast (PLN-74809)
Bexotegrast (developed by Pliant Therapeutics) is an oral, once-daily, selective small-molecule inhibitor of the alpha-v beta-6 and alpha-v beta-1 integrins. These integrins are upregulated in fibrotic lung tissue, where they bind and activate latent TGF-beta. By selectively blocking this activation pathway, bexotegrast prevents fibrogenesis without inducing the systemic toxicities associated with non-selective TGF-beta blockade. The Phase IIa INTEGRIS-IPF trial demonstrated that bexotegrast was well-tolerated and showed a dose-dependent reduction in FVC decline.
Pamrevlumab (FG-3019)
Pamrevlumab (developed by FibroGen) is a human monoclonal antibody that targets connective tissue growth factor (CTGF), a key mediator of tissue remodeling and fibrosis. While the Phase II PRAISE trial showed promising results on slowing FVC decline, subsequent Phase III trials have exhibited efficacy variance, leaving its regulatory pathway uncertain.
For a greater understanding of respiratory biologics and pipeline development, see the severe-asthma biologic access landscape.
Clinical Management of Gastrointestinal Intolerance in Antifibrotic Therapy
One of the principal clinical challenges in managing idiopathic pulmonary fibrosis is patient adherence, which is frequently compromised by gastrointestinal side effects. Clinical pharmacy teams must understand these side-effect profiles to implement proactive management protocols.
- Nintedanib (Ofev) Tolerability: Diarrhea is the most common adverse reaction, reported in 62% of patients in the INPULSIS trials. Nausea and vomiting are also common. Management requires immediate treatment with antidiarrheal agents (e.g., loperamide) and, if symptoms persist, a dose reduction from the standard 150 mg twice daily to 100 mg twice daily, or temporary treatment interruption. Liver enzyme monitoring is also required: if AST or ALT levels exceed 3 times the upper limit of normal (ULN), nintedanib must be interrupted and can only be resumed at the lower dose once enzymes return to baseline.
- Pirfenidone Tolerability: Gastrointestinal events like nausea, vomiting, and dyspepsia are common but can be minimized by taking the medication with food. Photosensitivity rash is a major drug-specific concern, requiring patients to use high-SPF sunscreen and avoid direct sun exposure.
- Nerandomilast (Jascayd) Tolerability: In the FIBRONEER-IPF trial, diarrhea occurred in 41% of patients on the 18 mg twice-daily dose compared to 16% of those on placebo. Nausea was reported in 18% of patients. When these symptoms occur, the dose can be reduced to 9 mg twice daily. However, because co-administration with pirfenidone increases pirfenidone plasma concentrations, Jascayd dose reductions are not recommended for patients on background pirfenidone.
Pharmacy Benefit Verification and Skinny Label Legal Liability
The launch of skinny-labeled generic nintedanib esylate introduces legal and operational verification requirements for pharmacy benefit managers and dispensing specialty pharmacies. Because the generic formulation is approved only for the treatment of IPF, its use in SSc-ILD or PF-ILD constitutes patent infringement of Boehringer Ingelheim's active method patents.
- Automated Reject Codes: Payers must implement diagnostic verification edits at the point of sale. Claims for generic nintedanib must require a matching ICD-10 code for idiopathic pulmonary fibrosis (e.g., J84.112). If the diagnosis matches systemic sclerosis-associated ILD (M34.81) or other progressive ILDs, the claim must reject, and the system must direct the dispensing pharmacy to fill brand-name Ofev.
- Dispensing Pharmacy Liability: Specialty pharmacies face potential legal liability if they knowingly dispense a skinny-labeled generic for a patent-protected indication. Pharmacists must verify the patient's specific indication through clinical intake and physician notes before dispensing the generic alternative.
- Audit Exposure: Payers should conduct retrospective audits on all nintedanib claims to ensure that patients who transitioned to generic formulations indeed have a primary diagnosis of IPF, safeguarding the plan against manufacturer patent litigation.
IPF Class Affordability & Pricing Benchmarks
To assist pharmacy directors in constructing formulary tiers, the table below consolidates the retail pharmacy acquisition cost benchmarks for the IPF class, compiled from the CMS NADAC snapshot.
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| IPF PRICING BENCHMARKS (CMS NADAC SNAPSHOT) |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Drug Name | Brand/Generic | NDC Code | NADAC Per Unit | Pricing Unit | Monthly Cost (30-Day Supply)* |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Pirfenidone 267 mg | Generic | 51224-0205-50 | $1.24964 | EA (Tablet) | $337.40 (90 tablets/month) |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Pirfenidone 801 mg | Generic | 00904-7128-04 | $4.11794 | EA (Tablet) | $370.61 (90 tablets/month) |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Pirfenidone 267 mg | Generic | 68180-0922-09 | $1.65150 | EA (Capsule) | $445.91 (90 capsules/month) |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Brand Ofev 100 mg | Brand (Specialty Only) | 00597-0143-60 | $0.00000 | Excluded (Specialty Network) | Specialty/Orphan Pricing |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Brand Ofev 150 mg | Brand (Specialty Only) | 00597-0145-60 | $0.00000 | Excluded (Specialty Network) | Specialty/Orphan Pricing |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Nintedanib 100 mg | Generic (Specialty Only)| 69097-0422-02 | $0.00000 | Excluded (Specialty Network) | Specialty Generic Pricing |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Nintedanib 150 mg | Generic (Specialty Only)| 69097-0424-02 | $0.00000 | Excluded (Specialty Network) | Specialty Generic Pricing |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Brand Jascayd 18 mg | Brand (Specialty Only) | 00597-0248-60 | $0.00000 | Excluded (Specialty Network) | Brand Specialty/Orphan Pricing |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
*Note: Monthly cost calculations assume standard twice-daily dosing (60 tablets/month) for nintedanib (Ofev) and nerandomilast (Jascayd); and standard three-times-daily dosing (90 tablets/month) for pirfenidone.
Payers should leverage these benchmarks to mandate generic pirfenidone or skinny-labeled generic nintedanib (for IPF diagnoses) over brand-name Ofev, reserving the brand solely for SSc-ILD and progressive ILD indications protected by remaining method-of-use patents.
FAQ Section
Is Ofev available as a generic in 2026, and for which indications?
Yes, generic nintedanib esylate (the active equivalent of Ofev) was approved by the FDA on April 2, 2026 following the expiration of Ofev's primary composition-of-matter patent. However, because Boehringer Ingelheim retains method-of-use patents covering non-IPF indications (such as systemic sclerosis-associated ILD, protected until July 2029), the approved generics are "skinny-labeled" and indicated only for the treatment of Idiopathic Pulmonary Fibrosis (IPF). For SSc-ILD and progressive ILD (PF-ILD) indications, brand-name Ofev remains the only approved option.
Can Jascayd (nerandomilast) be taken with pirfenidone or nintedanib?
Yes. In the Phase III FIBRONEER-IPF trial, approximately 70% of patients were receiving stable background therapy with either nintedanib or pirfenidone. The combination of nerandomilast with these background antifibrotics was shown to be safe and effective, providing an additive clinical effect on slowing lung-function decline. However, the Jascayd label notes a drug-drug interaction with pirfenidone: if a patient experiences tolerability issues on the standard 18 mg twice-daily dose of Jascayd, a dose reduction to 9 mg twice daily is not recommended if they are concurrently taking pirfenidone, as it can significantly increase pirfenidone plasma concentrations.
How does the IPF antifibrotic landscape compare on slowing lung-function decline?
Nintedanib (Ofev) and pirfenidone (Esbriet) demonstrate similar clinical efficacy, slowing the annual rate of FVC decline by approximately 50% (about 100 to 125 mL/year of saved lung volume). The choice between them is typically driven by side-effect profiles (diarrhea and liver enzyme elevations for nintedanib vs. photosensitivity rash and nausea for pirfenidone) and payer formulary preferences. Jascayd (nerandomilast) acts as a preferential PDE4B inhibitor rather than a direct kinase or TGF-beta blocker. In the FIBRONEER-IPF trial, Jascayd (as monotherapy or add-on to background nintedanib/pirfenidone) slowed FVC decline by an adjusted mean of 68.8 mL at 52 weeks compared to placebo, offering an additive benefit when combined with existing antifibrotic therapy.
Sources
- Richeldi, L., et al. "Efficacy and Safety of Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF)." New England Journal of Medicine, 2025. U.S. Food and Drug Administration / Boehringer Ingelheim. https://www.nejm.org/doi/full/10.1056/NEJMoa2414108
- U.S. Food and Drug Administration. Drugs@FDA approval records and ANDA approvals for nintedanib esylate (ANDA 212609, 219227, 219283, 216915, 219819; approved April 2, 2026). CDER database. https://www.accessdata.fda.gov/scripts/cder/daf/
- Richeldi, L., et al. "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis (INPULSIS-1 and INPULSIS-2)." New England Journal of Medicine, 2014. https://www.nejm.org/doi/full/10.1056/NEJMoa1402584
- King, T. E., et al. "A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (ASCEND)." New England Journal of Medicine, 2014. https://www.nejm.org/doi/full/10.1056/NEJMoa1402582
- Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Files, database update dated July 8, 2026. Medicaid Prescription Drug Pricing Resources. https://www.medicaid.gov/medicaid/prescription-drugs/registration/index.html
- Boehringer Ingelheim GmbH. "FDA Approves Jascayd (nerandomilast) for the Treatment of Idiopathic Pulmonary Fibrosis." BI Press Release. Published October 7, 2025. Accessed July 2026. https://www.boehringer-ingelheim.com/us/human-health/lung-diseases/pulmonary-fibrosis/fda-approves-new-treatment-option-adults-ipf
- GreyB Services. "Ofev Patent Expiration & Generic Competition Strategy Analysis." GreyB Research. Published April 2026. Accessed July 2026. https://greyb.com/blog/ofev-patent-expiration
- Dexcel Pharma. "Dexcel Pharma Announces FDA Approval and Commercial Launch of Generic Nintedanib Capsules." PR Newswire. Published April 2, 2026. Accessed July 2026. https://www.prnewswire.com/news-releases/nintedanib-capsules-approval-and-launch-302736226.html
